Nimotuzumab has shown clinical benefit when is used as monotherapy in recurrent or relapsed brain tumors in children, or in combination with RT in children with diffuse intrinsic pontine glioma (DIPG) or in adult with GBM, and this antitumor activity was observed in the absence of severe skin rash, acneiform rash, and any other dermatological or mucosal toxicities commonly associated with other EGFR‐targeting agents, such as cetuximab, panitumumab, and erlotinib 18, 19, 20, 21, 22. Here, EGFR is linked to diffuse intrinsic pontine glioma.